PMID- 37528440
OWN - NLM
STAT- MEDLINE
DCOM- 20231129
LR  - 20231129
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 37
IP  - 12
DP  - 2023 Dec
TI  - Predictive factors of atopic-like dermatitis induced by IL-17A inhibitors in 
      patients with psoriasis: A 2-year follow-up study.
PG  - 2509-2516
LID - 10.1111/jdv.19394 [doi]
AB  - BACKGROUND: Atopic-like dermatitis (ALD) is a common side effect of 
      interleukin-17A (IL-17A) inhibitors. OBJECTIVE: To determine the prevalence, risk 
      factors, outcomes and treatment of ALD in a cohort of psoriasis patients treated 
      with IL-17A inhibitors. METHODS: This retrospective study included 226 psoriasis 
      patients treated with an IL-17A inhibitor in our dermatology department between 
      July 2020 and July 2022. The patients were reviewed over 2 years. A logistic 
      regression model in rare events data (relogit) was used to predict the risk 
      factors for ALD. RESULTS: Of the 226 patients, 14 had ALD. Data including age, 
      body mass index, IL-17A inhibitor use, personal and family history of atopic 
      disease, pet ownership history, and immunoglobulin E (IgE) levels were analysed 
      using the relogit regression model. It indicated a personal history of atopic 
      disease (odd ratio [OR] 27.830, 95% confidence interval [CI] 3.801-203.770; 
      p = 0.001) and elevated IgE levels (OR 5.867, 95% CI 1.131-30.434; p = 0.035) as 
      independent predictors of incident ALD. In one patient, anti-IL-17A therapy was 
      discontinued, and treatment was switched to tofacitinib. Thirteen patients who 
      continued with IL-17A inhibitor were treated with topical therapy and/or 
      antihistamines, and their ALD was partially or completely resolved. CONCLUSION: 
      In this study, the incidence rate of ALD was 6.19%. Elevated IgE levels and a 
      personal history of atopic disease were found to be the risk factors for ALD. Our 
      study findings suggest that treatment should be provided based on the severity of 
      psoriasis and incident ALD. Prior to treatment, psoriasis patients who have the 
      risk factors for ALD should be informed of the possible development of ALD, and 
      alternative psoriatic therapeutic options should be considered if severe ALD 
      develops.
CI  - (c) 2023 European Academy of Dermatology and Venereology.
FAU - Tang, Xin
AU  - Tang X
AUID- ORCID: 0000-0002-8472-9637
AD  - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Li, Qian
AU  - Li Q
AD  - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - College of Traditional Chinese Medicine of Chongqing Medical University, 
      Chongqing, China.
FAU - Zheng, Xuyu
AU  - Zheng X
AD  - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Zhou, Cui
AU  - Zhou C
AD  - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Hu, Yulian
AU  - Hu Y
AD  - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Wang, Ping
AU  - Wang P
AUID- ORCID: 0000-0001-6181-3556
AD  - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Chen, Aijun
AU  - Chen A
AD  - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Huang, Kun
AU  - Huang K
AUID- ORCID: 0000-0002-7358-9560
AD  - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
LA  - eng
GR  - 2020FYYX017/Chongqing Science and Health Joint Medical Research Project/
GR  - 2020GDRC028/the High-level Medical Reserved Personnel Training Project of 
      Chongqing./
GR  - 81972942/the National Natural Science Foundation grants of China/
PT  - Journal Article
DEP - 20230809
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin Inhibitors)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - Interleukin-17
MH  - Follow-Up Studies
MH  - Interleukin Inhibitors
MH  - Retrospective Studies
MH  - *Psoriasis/drug therapy
MH  - *Dermatitis, Atopic/drug therapy
MH  - Immunoglobulin E
EDAT- 2023/08/02 01:07
MHDA- 2023/11/29 06:42
CRDT- 2023/08/01 23:40
PHST- 2023/01/20 00:00 [received]
PHST- 2023/06/30 00:00 [accepted]
PHST- 2023/11/29 06:42 [medline]
PHST- 2023/08/02 01:07 [pubmed]
PHST- 2023/08/01 23:40 [entrez]
AID - 10.1111/jdv.19394 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2509-2516. doi: 10.1111/jdv.19394. 
      Epub 2023 Aug 9.